Joined February 2012
- Tweets 913
- Following 89
- Followers 1,782
- Likes 512
368 Photos and videos
May 27
Last week, ProQR co-founder Dinko Valerio joined the team to reflect on ProQR’s journey from an ambitious idea to advancing our #Axiomer #RNAEditing platform in the clinic.
We are grateful to Dinko for his contributions over the years and for sharing his passion and insights.
6
407
May 15
Today is #MPSAwarenessDay.
#Hurlersyndrome is a severe form of MPS and is associated with significant disease burden, impacting quality of life and life expectancy.
We recently announced AX-0422, a potential #RNAEditing therapy in development for Hurler syndrome.
#ShineforMPS
3
233
May 12
We’re excited to share that ProQR will present new data across multiple scientific conferences this May, highlighting the breadth of our Axiomer™ RNA editing platform.
For more details, check out the PR: bit.ly/42qfJy9
#RNAEditing #Biotech
4
289
Apr 9
Drug discovery can be slow and patients are waiting.
Our CEO Daniel de Boer and Ginkgo CEO Jason Kelly sat together to discuss how our collaboration is accelerating our #Axiomer #RNAEditing platform development.
#Biotech #AI
3
11
3,839
Apr 9
Following our partnership announcement with @Ginkgo Bioworks, our CEO Daniel de Boer sat down with Ginkgo CEO Jason Kelly to discuss the opportunity ahead.
Hear how our #Axiomer #RNAEditing platform, automation, and data can accelerate drug development.
#Biotech #AI
1
6
5,673
Apr 8
Today we highlighted key updates in our Investor and Analyst event titled, “Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810.”
Check out the PR for more details: bit.ly/4tEAbXC and watch the replay of the event: bit.ly/3PZBL7N
#Axiomer #Biotech
3
285
Apr 8
In one hour, at 10:00 ET, we are hosting a virtual Investor and Analyst event titled, “Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810”.
For additional information about the event and to register, visit: lifescievents.com/event/g09g…
#Axiomer #RNAEditing
4
199
Apr 8
We’re excited to introduce our partnership with Ginkgo Bioworks and in addition our AI Advisory Board, helping to bring #Axiomer #RNAEditing therapies to patients faster.
Learn more at our Virtual Investor & Analyst event today at 10:00 ET: lifescievents.com/event/g09g…
12
4,857
Mar 25
On April 8th at 10:00 am ET, we are hosting a virtual Investor and Analyst event titled, “Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810”.
For additional information about the event and to register, visit: lifescievents.com/event/g09g…
#Axiomer #RNAEditing
2
6
435
Mar 12
Today we released our 2025 year end financial results and provided a business update.
Read the full press release on our website: bit.ly/46V5zIv
$PRQR #Biotech #Axiomer #RNAEditing
4
5,337
Mar 3
Driven by a deep curiosity about molecular biology, Seda translates emerging science into strategic direction as Senior Director, Research Strategy & Innovation at ProQR.
Explore Seda’s profile on our website: bit.ly/4aZHott
#RNAEditing #Axiomer
1
3
452
Feb 27
At #TIDESAsia in Tokyo, our Chief Scientific Officer, Gerard Platenburg, shared how we are translating #Axiomer #RNAEditing into liver and CNS applications.
You can explore the presentation here: bit.ly/4aCHSH6
2
317
Feb 11
Today we recognize the 11th anniversary of International Day of Women and Girls in Science! We caught up with Cristina Lopez Lopez, MD, PhD, CMO at ProQR, who shared her message for aspiring #WomenInScience.
#IDWGS2026 #Feb11 #EveryVoiceInScience
5
349
Feb 9
Today, ProQR announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company’s next AGM as their terms conclude.
We'd like to sincerely thank Dinko and Alison for their valuable contributions to ProQR during their tenures.
1
1,138
Jan 29
Carles is a Researcher at ProQR, combining a passion for biology with hands-on #RNAEditing research. Beyond the lab, he actively supports an inclusive and welcoming culture as part of the DEI team!
Meet more members of the ProQR team: bit.ly/3M09Gvm
#Axiomer #TeamProQR
1
277
Jan 8
Proud to share our latest update highlighting encouraging initial safety and PK data with AX-0810 (cholestatic diseases), Development Candidate selection for AX-2402 (Rett syndrome) and AX-2911 (MASH), and strong momentum heading into 2026 as we advance our #Axiomer platform.
1
4
14
1,405
Jan 8
3
301
22 Dec 2025
Our recent edition of the Axiomer Summit brought insightful discussions, a dynamic poster session, and exciting platform updates.
Thanks to our SAB and Board for their valuable contributions!
#RNAEditing #Axiomer #Biotech
3
463
21 Nov 2025
Great to connect with the community at #TIDESEU in Basel last week. Gerard Platenburg, our Chief Scientific Officer, presented on translating #Axiomer RNA Editing science into targeted CNS applications.
Check out the presentation here: bit.ly/3K2y927
#RNAEditing
1
7
1,377